AstraZeneca PLC Ordinary Shares (AZN)

Financing Cash Flow

-$7.72B

TTM · Period ending: · USD

AZN logo

AZN Financing Cash Flow

Latest reported-$7.72B
AZN TTM Cash from Financing (-$400.29M → -$7.72B)
High-resolution chart · PNG

AZN financing cash flow history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

AstraZeneca PLC Ordinary Shares Financing Cash Flow — Trailing twelve months (TTM) (USD)
Period endingFinancing Cash Flow (USD)
-7,722,017,393
-4,649,955,200
-7,623,955,200
-4,938,850,237
-6,991,000,000
-8,731,000,000
-3,996,000,000
-3,616,000,000
-2,211,000,000
-2,508,000,000
-6,567,000,000
-6,634,000,000
-5,338,000,000
-5,114,000,000
-6,823,000,000
-7,516,000,000
-5,944,000,000
2,640,000,000
3,649,000,000
2,490,000,000
3,591,000,000
-2,572,000,000
-2,203,000,000
13,000,000
-3,942,000,000
-3,429,000,000
-1,765,000,000
-3,503,000,000
-622,000,000
-2,079,000,000
-2,044,000,000
-324,000,000
-3,563,000,000
-1,557,000,000
-2,936,000,000
-3,228,000,000
-1,172,000,000
-2,005,000,000
-1,324,000,000
3,264,000,000
3,260,000,000
2,086,000,000
878,000,000
-2,255,000,000
-2,523,000,000
-3,062,000,000
-2,705,000,000
-3,655,000,000
-3,481,000,000
-3,027,000,000
-3,047,000,000
-3,773,000,000
-2,903,000,000
-3,751,000,000
-4,957,000,000
-6,113,000,000
-8,721,000,000
-8,952,000,000
-9,321,000,000
-9,460,000,000
-8,383,000,000
-7,845,000,000
-7,220,000,000
-5,336,000,000
-5,033,000,000
-4,557,000,000
-3,629,000,000
-5,156,000,000
-6,031,000,000
-6,221,000,000
-6,362,000,000
-5,093,000,000
-5,668,000,000
6,696,000,000
6,051,000,000
5,091,000,000
6,122,000,000
-6,760,000,000
-5,366,000,000
-4,964,000,000
-4,678,000,000
-4,656,000,000
-4,572,000,000
-6,696,000,000
-5,673,000,000
-4,605,000,000
-3,623,000,000
-2,214,000,000
-1,464,316,734
-2,366,809,117
-1,903,000,000
-2,878,913,713
-3,098,037,004
-3,292,981,559
-3,312,000,000
-1,536,535,109
-2,020,283,659
-1,338,639,857
-1,370,886,128
-764,345,390
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.